News und Analysen
What Caused Arrowhead Pharmaceuticals to Skyrocket 10.5% Today
After the company announced it has filed for approval with New Zealand regulators to begin phase 1 studies of its hepatitis B RNAi therapy, shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)....
Bayer Jumps Into Mergers and Acquisitions With $1.7 Billion Deal
On the heels of Bayer AG (NASDAQOTH: BAYRY) licensing Loxo Oncology's (NASDAQ: LOXO) fusion-targeting cancer drug, Roche Holdings (NASDAQOTH: RHHBY) is acquiring Ingynta (NASDAQ: RXDX), a company....
Roche Jumps Into Mergers and Acquisitions With $1.7 Billion Deal
On the heels of Bayer AG (NASDAQOTH: BAYRY) licensing Loxo Oncology's (NASDAQ: LOXO) fusion-targeting cancer drug, Roche Holdings (NASDAQOTH: RHHBY) is acquiring Ingynta (NASDAQ: RXDX), a company....
Why These Bitcoin Stocks Are Tumbling Today
Shares of three stocks, Riot Blockchain (NASDAQ: RIOT), Overstock.com (NASDAQ: OSTK), and Seven Stars Cloud Group (NASDAQ: SSC), that have ridden cryptocurrency mania to explosive gains tumbled on....
Bitcoin Plunges 20% -- Is the Rally Over?
It's been a tough week for cryptocurrencies in general, and bitcoin in particular. After reaching an all-time high of almost $20,000 just a week ago, bitcoin hit a low of $10,400 on Coinbase....
Ask a Fool: Are Any Bitcoin Stocks Worth Buying?
I consider bitcoin and other digital currencies to be highly speculative investments, and people shouldn't buy them with any money they can't afford to lose.Stocks of companies that could profit....
3 Reasons to Own Pfizer's Stock in 2018
Despite losing nearly $30 billion in branded pharma sales due to the loss of exclusivity for key brands like Celebrex, Lipitor, Lyrica, and Viagra over the course of 2011 to 2020, Pfizer (NYSE:....
Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
It's been a great year for most investors, with the S&P 500 index rising close to 20% in 2017. But not every stock has performed that well. The stocks of two S&P 500 members,....
Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)
If AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summer, AbbVie would have pulled....
2018's 3 Biggest Catalysts for Marijuana Stocks
Forget seeing marijuana stocks go up in smoke in 2017. They've been smoking hot.According to cannabis research firm ArcView, the North American legal weed industry is expected to grow by 26% a....
If I Could Only Buy 1 Healthcare Stock in January, It Would Be This One
Pfizer Inc. (NYSE: PFE) is the one healthcare stock I'd add to my portfolio in January. Why? The company's turning the corner back toward growth, its R&D team is delivering important wins, its....
3 Promising Cancer Immunotherapies to Watch in 2018
Any way you look at it, immunotherapies -- also known as immuno-oncology (I-O) drugs -- are hot commodities. Two of the top three cancer drugs projected to be the biggest winners in the next five....
3 Best Marijuana Biotech Stocks for 2018
Next year should be enormously important for Canadian marijuana stocks, as the country moves forward with legalization of recreational marijuana. But that milestone means little for biotechs....
VISIOMED GROUP complète sa levée de fonds de décembre 2017 pour répondre à la demande des investisseurs
Paris, le 22 décembre 2017
VISIOMED GROUP (FR0011067669 – ALVMG), société spécialisée dans l'électronique médicale nouvelle génération, annonce la réalisation d'une augmentation de 1,7 M€.....
Why Corcept Therapeutics Shares Climbed 10.8% Today
After news broke that shares will soon be included in the S&P Small Cap 600 index, Corcept Therapeutics' (NASDAQ: CORT) stock price jumped by 10.8% today.The addition to the S&P 600 Small....
Better Stock: Veeva Systems (VEEV) vs. Cerner (CERN)
Few industries have given shareholders returns like those of the healthcare sector over the past few decades. Two companies at the forefront of that tide are Veeva Systems (NYSE: VEEV) and Cerner....
Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
Exelixis, Inc. (NASDAQ: EXEL) has already delivered big gains this year, but there could be a few untapped veins in this biotech gold mine. We'll need to tread lightly because a great deal of....
Why 2017 Was a Year to Remember for Intuitive Surgical, Inc.
Stocks of companies with solid business models and products that meet needs tend to perform well over the long run. Intuitive Surgical, Inc. (NASDAQ: ISRG) is a good example. The robotic surgical....
Exelixis' Cabometyx Takes Aim at Sutent in Kidney Cancer
After reporting in 2016 that its second-line kidney cancer drug, Cabometyx, outperformed Pfizer Inc.'s (NYSE: PFE) top-selling Sutent in first-line advanced kidney cancer patients, Exelixis....
3 Top Generic Drug Stocks to Consider Buying Now
Brand-name drugs tend to capture all the headlines, but did you know that nine out of every 10 prescriptions filled in the U.S. each year are generic? When added together, Americans spend spent....
Portola Pharmaceuticals Gets a Surprise Present From the FDA
The FDA approved Portola Pharmaceuticals' (NASDAQ: PTLA) first commercial drug, Bevyxxa, in June, but changes to its manufacturing process resulted in the filing of a prior approval supplement....
What to Expect From Corbus Pharmaceuticals in 2018
For a brief few weeks in 2017, it looked like Corbus Pharmaceuticals (NASDAQ: CRBP) could be making another big play after a terrific performance in the previous year. The stock gained more than....
What to Expect From Celgene Corporation in 2018
After two years of lackluster performances, Celgene Corporation (NASDAQ: CELG) appeared to be on a roll in 2017. Then the bottom fell out.In October, the big biotech stock gave up all of its....
Aerie Pharmaceuticals Nabs FDA OK for Glaucoma Drug
Aerie Pharmaceuticals' (NASDAQ: AERI) Rhopressa has secured Food and Drug Administration approval for use as an alternative to beta blockers in glaucoma patients that fail to respond adequately to....
The FDA Just Approved a Game-Changing Therapy for Blindness
A decision on Spark Therapeutics' (NASDAQ: ONCE) vision-restoring gene therapy, Luxturna, was expected next month, but the Food and Drug Administration decided an early OK was warranted following....